• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

1999 Fiscal Year Final Research Report Summary

Immunologic and molecular analysis of diffuse large B-cell lymphoma

Research Project

Project/Area Number 10670167
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Human pathology
Research InstitutionFukushima Medical University School of Medicine

Principal Investigator

NAKAMURA Naoya  Fukushima Medical University, Sch. of Med., Instructor, 医学部, 講師 (50227922)

Co-Investigator(Kenkyū-buntansha) HOSHI Sayuri  Fukushima Medical University, Sch. of Med., Assistant Instructor, 医学部, 助手 (20285026)
NOZAWA Yoshihiro  Fukushima Medical University, Sch. of Med., Instructor, 医学部, 講師 (40208343)
HOJO Hiroshi  Fukushima Medical University, Sch. of Med., Assistant Prof., 医学部, 助教授 (90209213)
Project Period (FY) 1997 – 1999
KeywordsIgH gene / PCR / Somatic mutation / RT-PCR / Diffuse large B-cell lymphoma
Research Abstract

We analyzed diffuse large B-cell lymphoma (DLBCL) using hitologic, immunologic and molecular technique. A total of 120 cases of DLBCL examined comprised 83 cases of centroblastic variant (CB), T-cell or histiocyte rich variant (TCHR). Immunologic profiles of our series was as follows: CD5-positive cases/examined cases; CB 12/83, IB 0/12, ALB 0/18 and TCHR 0/7, CD 10-positive cases/ examined cases; CB 8/83, IB 1/12, ALB 0/18 and TCHR 0/7, and bcl 6-positive cases/examined cases; CB 55/67, IB 5/6, ALB 3/10 and 1/6 in TCHR. Infection of Epstein Barr Virus (EBV) was performed using EBER-1 RNA in situ hybridization. EBV was harbored in the lymphoma cells of 5/82 in CB, 0/12 in IB, 6/18 in ALB and 1/6 in TCHR. The distribution of somatic mutation of immunoglobulin heavy chain gene variable region was ranged 0.7-12.9% with an average of 6.2% in CD5ィイD1+ィエD1CB (10 cases), 2.0-25.9% with an average of 11.1% in CD5ィイD1-ィエD1CB (29 cases), 5.4-30.2% with an average of 13.5% in IB (3 cases), 0-12.5% with an average of 8.2% in ALB (9 cases) and 6.8-17.0% with an average of 10.7% in ALB (4 cases). The mRNA of β-actin, CD10, PAX-5, RAG-1 and alkaline phosphatase were amplified by RT-PCR. The RT-PCR products were found in 14/14 (β-actin), 2/14 (CD10), 3/14(PAX-5), 3/14(RAG-1) and 0/14(alkaline phosphatase). These data indicated that the histogenesis of CD5-positive DLBCL was different from that of CD5-negative DLBCL belonged to the neoplasms of B2 cells. The clinical outcome of CD5-positive DLBCL was worse than that of CD5-negative DLBCL. CD5-negative DLBCL may still involve various kinds of DLBCL, such as transformed DLBCL from follicular lymphoma and DLBCL with differentiation to plasma cells.

  • Research Products

    (4 results)

All Other

All Publications (4 results)

  • [Publications] Naoya Nakamura: "Analysis of the immunoglobulin heavy chain gene variable region of 101 cases with peripheral b-Cell neoplasms and B cell chronic lymphocytic leukemia in the japanese population"Pathology Intrnational. 49. 595-600 (1999)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Naoya Nakamura: "Analysis of the immunogobulin heavy chain gene variable region of CD5-positive diffuse large B-cell lymphoma"Laboratory Investigation. 79. 925-933 (1999)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] NAKAMURA,Naoya, KUZE,Tetsuo, HASHIMOTO,Yuko, TASAKI,Kazuhiro, HOJO,Hiroshi, SASAKI,Yoshikazu, SATO,Michiko, ABE,Masafumi: "Analysis of the immunoglobulin heavy chain gene variable region of 101 cases with peripheral B-cell neoplasms and B cell chronic lymphocytic leukemia in the Japanese population."Pathology International. 49. 595-600 (1999)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] NAKAMURA,Naoya, KUZE,Tetsuo, SASAKI,Yoshikazu, SATO,Michiko, ABE,Masafumi: "Analysis of the immunoglobulin heavy chain gene variable region of CD5-positive diffuse large B-cell lymphoma."Laboratory Investigation. 79. 925-933 (1999)

    • Description
      「研究成果報告書概要(欧文)」より

URL: 

Published: 2001-10-23  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi